PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Adamis Pharmaceuticals Corp (DMK)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US00547W3079

WKN

A3EEVQ

Sector

Healthcare

IPO Date

Aug 14, 1995

Highlights

Market Cap

$6.81M

EPS (TTM)

-$5.78

Year Range

$0.03 - $0.23

Target Price

$1.50

Short %

2.36%

Short Ratio

0.13

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Adamis Pharmaceuticals Corp, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


DMK (Adamis Pharmaceuticals Corp)
Benchmark (^GSPC)

Returns By Period


DMK

YTD

N/A

1M

N/A

6M

N/A

1Y

N/A

5Y*

N/A

10Y*

N/A

^GSPC (Benchmark)

YTD

3.96%

1M

1.97%

6M

9.03%

1Y

22.16%

5Y*

12.60%

10Y*

11.26%

*Annualized

Monthly Returns

The table below presents the monthly returns of DMK, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2024-22.86%-83.67%-41.04%32.69%236.23%-66.86%
202317.65%10.00%-45.45%-33.33%-62.68%15.31%-40.66%-43.36%-14.81%-26.09%5.88%29.63%-94.12%
2022-1.64%6.67%-10.94%-31.58%25.64%2.04%-24.00%-13.16%-39.39%-30.00%42.86%-15.00%-72.13%
2021134.69%-2.61%-16.07%-15.96%-12.66%59.42%7.27%-7.63%-11.01%8.25%-21.90%-25.61%24.49%
2020-5.71%-13.64%-36.84%44.44%-5.77%10.20%118.52%-44.07%18.18%-8.97%-39.44%13.95%-30.00%
201936.44%-3.58%-28.72%-2.84%-26.34%-13.91%-11.54%-18.26%-25.53%15.71%-28.40%20.69%-68.89%
2018-17.05%-17.81%16.67%2.86%19.44%-25.58%-0.00%-10.94%22.81%-26.86%19.14%-26.23%-48.86%
2017-1.59%11.29%23.19%-12.94%4.05%35.06%-11.54%18.48%-4.04%-0.57%-26.92%15.79%39.68%
2016-12.04%22.11%5.69%34.58%5.09%-67.70%0.36%4.98%16.27%-24.78%8.53%12.50%-41.67%
201510.53%-5.87%-38.63%9.14%-0.70%-1.64%-0.24%-12.65%5.74%11.63%5.32%18.68%-12.48%
20144.23%-0.15%-4.36%-14.78%4.43%-15.02%-21.62%6.63%16.42%0.21%-11.94%49.39%-3.44%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of DMK is 49, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of DMK is 4949
Overall Rank
The Sharpe Ratio Rank of DMK is 3737
Sharpe Ratio Rank
The Sortino Ratio Rank of DMK is 7070
Sortino Ratio Rank
The Omega Ratio Rank of DMK is 9292
Omega Ratio Rank
The Calmar Ratio Rank of DMK is 4949
Calmar Ratio Rank
The Martin Ratio Rank of DMK is 00
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Adamis Pharmaceuticals Corp (DMK) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


Sharpe ratio
No data
DMK
^GSPC

There is not enough data available to calculate the Sharpe ratio for Adamis Pharmaceuticals Corp. We calculate this metric based on the past 12 months of trading data. Please check back later for updated information.


Rolling 12-month Sharpe Ratio
DMK (Adamis Pharmaceuticals Corp)
Benchmark (^GSPC)

Dividends

Dividend History


Adamis Pharmaceuticals Corp doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


DMK (Adamis Pharmaceuticals Corp)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Adamis Pharmaceuticals Corp. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Adamis Pharmaceuticals Corp was 100.00%, occurring on Feb 15, 2024. The portfolio has not yet recovered.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-100%Nov 23, 19996096Feb 15, 2024
-73.29%Jun 11, 1996271Jul 7, 199795Nov 18, 1997366
-70.07%Nov 19, 1997197Sep 1, 1998296Nov 3, 1999493
-35.19%Aug 25, 199576Dec 12, 199541Feb 9, 1996117
-22.22%Feb 12, 199627Mar 20, 199640May 16, 199667

Volatility

Volatility Chart

The current Adamis Pharmaceuticals Corp volatility is 121.26%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


DMK (Adamis Pharmaceuticals Corp)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Adamis Pharmaceuticals Corp over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Historical P/E Ratio Chart

The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Adamis Pharmaceuticals Corp.


Loading data...

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab